Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.650
-0.250-4.24%
Volume:2.93M
Turnover:16.36M
Market Cap:9.02B
PE:-17.95
High:5.895
Open:5.895
Low:5.420
Close:5.900
52wk High:10.410
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.62
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-52.14%
ROA:-14.44%
PB:5.96
PE(LYR):-17.95
PS:18.12

Loading ...

CStone Pharmaceuticals shareholders pass AGM resolutions

Reuters
·
Jun 24

CSTONE PHARMA-B Repurchases 500,000 Shares for HK$2.35 Million

Stock News
·
Jun 22

CStone Pharmaceuticals files HKEX next-day disclosure, reports share repurchase for cancellation

Reuters
·
Jun 22

CStone Pharmaceuticals repurchases 500,000 shares at up to HK$4.63; June buybacks total 2.84 million shares

Bulletin Express
·
Jun 18

CStone Pharmaceuticals-B Repurchases 500,000 Shares for HK$2.3143 Million on June 18

Stock News
·
Jun 18

CStone files HKEX next-day disclosure return, reports share repurchase for cancellation

Reuters
·
Jun 18

CStone Pharmaceuticals Repurchases 1.00 Million Shares on 17 June; Cumulative Buyback Reaches 2.34 Million Shares

Bulletin Express
·
Jun 17

Directors and Company Execute Major Share Purchases and Buyback at CSTONE PHARMA-B

Stock News
·
Jun 17

CStone Pharma repurchases 1.33 million shares for HK$6.23 million, equal to 0.08% of share capital

Bulletin Express
·
Jun 16

CSTONE PHARMA-B Repurchases 1.33 Million Shares for HK$6.2278 Million on June 16

Stock News
·
Jun 16

CStone files HKEX next-day disclosure return on share repurchase for cancellation

Reuters
·
Jun 16

CStone says 4,270,000 RSU grant to CEO Yang needs independent shareholder approval under HK rules

Reuters
·
Jun 16

CStone proposes 7 million stock options, 4.27 million RSUs for CEO Yang Jianxin

Reuters
·
Jun 16

CStone Pharmaceuticals-B Executes Share Buyback, Spending HK$28,000 on June 15

Stock News
·
Jun 15

CStone files HKEX next-day disclosure return after share repurchase for cancellation at HKD 4.66

Reuters
·
Jun 15

Key Biotech Stock Surges in Late Trading on Clinical Trial Progress and Insider Buying

Stock News
·
Jun 12

CStone says CS2009 posts 81.3% ORR in first-line PD-L1-high NSCLC Phase I study at ASCO 2026

Reuters
·
Jun 12

CStone Pharmaceuticals Drug Receives Ethics Approval in Australia

MT Newswires Live
·
Jun 12

Directors' Major Share Purchases Signal Confidence in Drug Developer's Long-Term Prospects

Stock News
·
Jun 12

CStone Pharma-B Launches Global Phase I Trial for Key ADC Candidate CS5007

Stock News
·
Jun 12